Claus Bo Svendsen
Dr. Claus Bo Svendsen, MD, PhD has been the Chief Executive Officer and Principal Financial Officer of Forward Pharma A/S since March 1, 2017 and May 2017 respectively. Dr. Svendsen served as Executive Vice President at Forward Pharma A/S from December 2, 2016 to March 1, 2017 and also served as its Vice President of Medical Affairs since June 24, 2016 until December 2, 2016. Dr. Svendsen is responsible for all Medical Affairs activities, including scientific communication strategy and additionally for medical and scientific input into clinical development across all phases of clinical trials. He was a Medical Analyst and Medical Consultant at NB Capital ApS. He joined NB Capital ApS in November 2008. Dr. Svendsen is a Medical Doctor from the University of Copenhagen and has clinical experience from primarily internal medicine and also from surgical departments. Prior to joining Forward Pharma in 2015, he held positions of increasing seniority in the Danish pharmaceutical company Novo Nordisk A/S, including roles of Global Medical Director for Victoza® (liraglutide) late-phase launch in type 2 diabetes and phase III development in type 1 diabetes and for Saxenda® in its regulatory and pre-launch phase for weight management, supporting a successful FDA advisory committee meeting and finally FDA and EMA approval and these roles included management in a matrix organization and global oversight of project-related medical activities. From 2007 to 2009, he worked as a Medical Analyst in Nordic Biotech Advisors ApS, dealing with due diligence of potential investment opportunities.
He has research experience from employment at the department of Bacteriology, Mycology and Parasitology at Statens Serum Institut, Copenhagen. Dr. Svendsen’s research has been focusing on sarcoidosis and chronic bacterial infections as well as pulmonary hypertension related to sarcoidosis. He is the author of more than ten papers in international peer-reviewed journals and serves as a Reviewer on the journal of Epidemiology and Infection and World Journal of Pediatrics. He has worked in several countries with a clinical background in internal medicine. He is a recipient of a Young Investigator Award from the Foundation for Sarcoidosis Research in 2009. Dr. Svendsen is an author of 27 publications in international, peer-reviewed journals and >50 abstracts presented at international congresses on pathobiology of sarcoidosis, new molecular biological methods and medical treatment of diabetes and obesity. Dr. Svendsen has held part of his education at a laboratory in Geelong, Victoria, Australia. He graduated as a Medical Doctor from University of Copenhagen in 2003 and completed a PhD in sarcoidosis pathobiology in 2009.